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Background: The plasma levels of cell-free DNA (cfDNA) are known to be elevated
under inﬂammatory or apoptotic conditions. Increased cfDNA levels have been re-
ported in hemodialysis (HD) patients. The aim of this study was to investigate the
clinical signiﬁcance of cfDNA in HD patients.
Methods: A total of 95 patients on HD were enrolled. We measured their pre-
dialysis cfDNA levels using real-time EIF2C1 gene sequence ampliﬁcation and
analyzed its association with certain clinical parameters.
Results: The mean plasma cfDNA level in the HD patients was 3,884 ± 407 GE/mL,
and the mean plasma cfDNA level in the control group was 1,420 ± 121 GE/mL (P <
0.05). Diabetic patients showed higher plasma cfDNA levels compared with
nondiabetic patients (P < 0.01). Patients with cardiovascular complications also
showed higher plasma cfDNA levels compared with those without cardiovascular
complication (P < 0.05). In univariable analysis, the cfDNA level was associated with
3-month mean systolic blood pressure (SBP), white blood cell, serum albumin,
creatinine (Cr), normalized protein catabolic rate in HD patients. In diabetic patients,
it was signiﬁcantly correlated with SBP, hemoglobin A1c, and serum albumin. In
multivariate analysis, SBP was the independent determinant for the cfDNA level. In
diabetic patients, cfDNA level was independently associated with hemoglobin A1c
and SBP.
Conclusions: In patients with HD, cfDNA is elevated in diabetic patients and pa-
tients with cardiovascular diseases. Uncontrolled hypertension and poor glycemic
control are independent determinants for the elevated cfDNA. Our data suggest that
cfDNA might be a marker of vascular injury rather than proinﬂammatory condition
in HD patients.
Copyright © 2015. The Korean Society of Nephrology. Published by Elsevier Ltd. This
is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).y, Department of Internal
t Gangdong, College of
149, Gangdong-gu, Seoul
.
iety of Nephrology. Published
y-nc-nd/4.0/).Introduction
First described in 1948 by Mandel and Metais, circulating
plasma cell-free DNA (cfDNA) is nucleic acids in peripheral
blood that originate from cell death caused by injury, apoptosis,
and necrosis [1,2]. cfDNA is normally found in small amounts inby Elsevier Ltd. This is an open access article under the CC BY-NC-ND
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levels have been reported in patients with various clinical
conditions including infection, inﬂammation, malignancy,
connective tissue diseases, ischemic stroke, myocardial infarc-
tion, pregnancy-associated disorders, and hemodialysis (HD)
[3e12]. cfDNA has been the focus of research because of its
potential use as a tool to diagnose malignant disease and to
monitor the severity of injury caused by several diseases.
Recently, Tovbin et al [13] have reported that postdialysis
cfDNA levels are an independent predictor of all-cause mor-
tality in patients undergoing HD.
End-stage renal disease (ESRD) patients undergoing HD are
characterized by proinﬂammatory conditions. In dialysis pa-
tients, chronic sterile inﬂammation is related to innate and
adaptive immune system activations, which result in an
increased level of inﬂammatory cytokines. In previous studies,
increased cfDNA levels were reported in HD patients, and
cfDNA is able to selectively induce the production of interleukin
6 (IL-6) in human monocytes [14]. However, limited data are
available concerning the clinical relevance of cfDNA in HD pa-
tients. The aim of this study was to investigate the clinical
signiﬁcance of cfDNA in patients undergoing maintenance HD.
Methods
Patients
The 95 ESRD patients undergoing maintenance HD and the
15 healthy controls were enrolled in the study in April 2015.
The ESRD patients underwent 4 hours of HD per session, 3
times per week. Patient medical record was collectedTable 1. Baseline clinical characteristics of 95 hemodialysis patients
Total (n ¼ 95)
Cause of ESRD (%)
Diabetic nephropathy 46 (48.4)
Hypertension 21 (22.1)
GN 15 (15.7)
Others 3 (3.1)
Unknown 10 (10.5)
Comorbidities (%)
CVA 21 (21.9)
CAD 13 (13.5)
CHF 21 (21.9)
Total CV complication 43 (45.3)
History of malignancy 7 (7.3)
Age (y) 58.0 ± 1.5
BMI (kg/m2) 23.4 ± 0.4
Mean dialysis duration (mo) 48.8 ± 5.3
WBC (103/mL) 5,883.4 ± 157.2
hsCRP (mg/L) 3.3 ± 0.9
SBP (mmHg) 141.0 ± 1.7
DBP (mmHg) 80.8 ± 0.7
HbA1c (%) 6.8 ± 0.2
Kt/V 1.5 ± 0.03
LDL (mg/dL) 78.2 ± 2.1
Total cholesterol (mg/dL) 139.6 ± 3.3
TG (mg/dL) 112.2 ± 6.1
HDL (mg/dL) 43.2 ± 1.2
Albumin (g/dL) 3.9 ± 0.03
nPCR (g/kg/d) 0.95 ± 0.04
BUN (mg/dL) 64.0 ± 2.1
Cr (mg/dL) 9.6 ± 0.3
BMI, body mass index; BUN, blood urea nitrogen; CAD, coronary artery disea
cerebrovascular accident; DBP, diastolic blood pressure; DM, diabetes melli
moglobin A1c; HDL, high-density lipoprotein; hsCRP, high-sensitivity C-rea
catabolic rate; SBP, systolic blood pressure; TG, triglyceride; WBC, white bloretrospectively, and it composed of the underlying causes of
ESRD, comorbidities, and clinical data including age, body mass
index (BMI), duration of HD, systolic blood pressure (SBP),
diastolic blood pressure, and laboratory ﬁndings such as mean
level of white blood cell (WBC), high sensitivity C-reactive
protein (hsCRP), hemoglobin A1c (HbA1c), marker of dialysis
adequacy Kt/V, normalized protein catabolic rate (nPCR), low
density lipoprotein (LDL), total cholesterol, triglyceride (TG),
blood urea nitrogen (BUN), and creatinine (Cr) during last 3
months. The cause of ESRD was categorized as diabetes
mellitus (DM), hypertension, glomerulonephritis (GN), other, or
unknown. All of blood samples were done before HD session.
As proinﬂammatory marker, cfDNA level might be affected by
any infection. Therefore, among HD patients, we excluded pa-
tients with signs of current infection such as WBC >10,000,
fever, and symptoms for urinary tract infection and respiratory
tract infection. In 95 HD patients, the mean value of hsCRP was
3.340 ± 0.9. Patients with recent (less than 1 month) history of
cardiovascular (CV) complications including cerebrovascular
disease and myocardial infarction and history of an interven-
tion for vascular access were also excluded.
The study was approved by the local ethics committee, and
patients provided signed informed consent before entering the
study.
cfDNA analysis
We extracted cfDNA from a 1-mL plasma sample using a
QIAamp Circulating Nucleic Acid Kit (Qiagen, Valencia, CA,
USA). As described in the manufacturer's protocol, the samples
were treatedwith proteinase K to inactivate DNases and RNasesNon-DM (n ¼ 45) DM (n ¼ 50) P
<0.001
0 46 (92)
18 (40) 3 (6)
15 (33.3) 0
2 (4.4) 1 (2)
10 (22.2) 0
7 (15.5) 14 (28) 0.14
4 (8.9) 9 (18) 0.20
8 (17.8) 13 (26) 0.34
17 (37.8) 26 (52) 0.03
2 (4.4) 5 (10) 0.30
55.4 ± 2.4 66.4 ± 1.8 0.09
21.8 ± 0.5 24.8 ± 0.6 0.18
56.9 ± 7.9 42.5 ± 6.9 0.18
5,447.6 ± 212.6 6,255.6 ± 215.7 0.98
2.9 ± 0.7 3.8 ± 1.5 0.59
136.3 ± 2.4 145.3 ± 2.3 0.68
80.1 ± 0.9 81.4 ± 0.9 0.68
5.5 ± 0.2 7.3 ± 0.3 0.11
1.6 ± 0.04 1.5 ± 0.04 0.01
81.9 ± 3.3 74.7 ± 2.7 0.09
144.7 ± 5.4 135.0 ± 4.0 0.15
97.2 ± 5.4 125.0 ± 10.0 0.02
45.1 ± 1.8 41.5 ± 1.6 0.15
3.9 ± 0.1 3.9 ± 0.04 0.73
0.91 ± 0.06 0.98 ± 0.05 0.37
64.0 ± 3.0 62.9 ± 2.9 0.79
10.3 ± 0.5 8.9 ± 0.4 0.03
se; CHF, congestive heart failure; Cr, creatinine; CV, cardiovascular; CVA,
tus; ESRD, end-stage renal disease; GN, glomerulonephritis; HbA1c, he-
ctive protein; LDL, low-density lipoprotein; nPCR, normalized protein
od cell.
Figure 1. Plasma level of cell-free DNA in HD patients. (A) Cell-free DNA
levels in the controls and DM and non-DM HD patients. (B) Correlation
between the cell-free DNA and HbA1c levels in diabetic HD patients.
*P < 0.05 compared with the controls.
yP < 0.05 compared with the non-DM HD patients.
cfDNA, cell-free DNA; DM, diabetes mellitus; HbA1c, hemoglobin A1c; HD,
hemodialysis.
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and carrier RNA was added to enhance the binding of nucleic
acids to the membrane. The lysate was run through a DNA
binding column and washed multiple times with buffers and
100% ethanol using the QIavac 24 Plus. The DNA was eluted in
50 mL of the supplied elution buffer. Circulating cfDNA was
quantiﬁed using real-time (RT) polymerase chain reaction
(PCR) with Chromo 4 RT PCR system (Bio-Rad, Hercules, CA,
USA) using custom Taqman gene expression assays for EIF2C1
and Taqman master mix (Applied Biosystems, Foster City, CA,
USA).The following primer sequences were used: forward 50-
CCT GCA GCA GGT GTT CCA -30; reverse 50- GCC AGG AGC TTG
ATT GGT TTC -30; and probe 50- FAM-CAC AGT GCC AAT GCC A
-NFQ-30 or forward 50- GCC GGC CTG GCA TTG -30; reverse 50-
GAT CTTAGGGAT GTC CAC CTC AAA -30; and probe 50- FAM-CTC
CTG GCC AAT TAC -NFQ-30. A standard curve was created using
serial diluted human genomic DNA: Male (Promega, Madison,
WI, USA). The DNA concentrationwas expressed and calculated
as genome equivalents/mL (GE/mL).
Statistical analysis
The baseline characteristics were presented as the mean,
standard deviation, and frequency and then compared using an
independent sample test. In case of continuous variables, cor-
relations between variables were analyzed using the Pearson's
correlation coefﬁcient. We used a multiple regression analysis
to evaluate the laboratory and clinical variables independently
associated with cfDNA level by dividing 2 groups in chronic HD
patients and in diabetic HD patients, as well as the factors that
were signiﬁcantly associated with cfDNA (P < 0.05). Statistical
analyses were performed using SPSS software, version 18
(PASW, Chicago, IL, USA).
Results
The baseline characteristics of the studied patients
Table 1 lists the baseline characteristics of the 95 HD pa-
tients (mean overall patient age, 58 ± 1.5 years; mean duration
of dialysis, 48.8 ± 5.3 months). The mean age of the healthy
controls was 32.8 ± 1.2 years. The main causes of ESRD were
diabetic nephropathy (48.4%), hypertension (22.1%), and GN
(15.7%). We deﬁned CV complication (total CV complication) as
cerebrovascular accidents, coronary artery disease, or conges-
tive heart failure, and Table 1 shows that total CV complication
was signiﬁcantly higher in diabetic HD groups than nondiabetic
HD patients (P ¼ 0.03). In other parameters, demographic fac-
tors such as age, BMI, and mean dialysis duration were not
statistically different. But Kt/V and Cr were higher in nondia-
betic HD group than those in diabetic HD group (P < 0.05,
respectively) and TG was higher in diabetic group than that in
nondiabetic group.
cfDNA levels and comorbid condition in HD patients
The mean plasma cfDNA level was 3,884 ± 407 GE/mL in the
HD patients, and it was signiﬁcantly higher than that of healthy
controls (1,420 ± 121 GE/mL). Diabetes is the most common
cause of ESRD and is awell-known sterile inﬂammatory disease.
We evaluated the difference in cfDNA levels between the dia-
betic and nondiabetic HD patients. The cfDNA levels weresigniﬁcantly higher in the diabetic HD patients compared with
those in the nondiabetic HD patients (4,612 ± 640 vs. 2,858 ±
385GE/mL, respectively, P< 0.01, Fig.1A). The cfDNA levelswere
also correlatedwithHbA1c levels in thediabeticHDpatients (r¼
0.37, P ¼ 0.003, Fig. 1B). In addition, we also evaluated the dif-
ference in cfDNA levels between the 43 patients who had total
CV complication and 53 patients without total CV complication.
The cfDNA levels were signiﬁcantly higher in the total CV
complication group than in those without CV complication
(2,193±322GE/mLvs.1,573±206GE/mL, respectively,P<0.05).
cfDNA levels and clinical parameters in HD patients
We evaluated the clinical factors associated with log value of
cfDNA (log cfDNA) in the HD patients through correlation
analysis. Three-month mean WBC counts (r ¼ 0.32, P ¼ 0.002,
Fig. 2A), SBP (r ¼ 0.36, P < 0.001, Fig. 2B), Cr (r ¼ 0.06, P ¼ 0.02,
Fig. 2C), albumin (r ¼ 0.75, P ¼ 0.2, Fig. 2D), and nPCR (r ¼ 0.26,
P ¼ 0.02, Fig. 2E) were signiﬁcantly correlated with log cfDNA.
However, there was no association with age, sex, hemoglobin,
uric acid, Ca, Ca P, low-density lipoprotein. In addition, hsCRP
was not signiﬁcantly associated with log cfDNA. Because cfDNA
was signiﬁcantly increased in diabetic patients, we additionally
evaluated the association of clinical parameters and log cfDNA
in diabetic HD patients. The SBP (r ¼ 0.35, P ¼ 0.12), HbA1c
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Figure 2. Correlation between clinical parameters and cfDNA (log). (A) WBC counts (r ¼ 0.32, P ¼ 0.002), (B) SBP (r ¼ 0.36, P < 0.001), (C) Cr (r ¼ 0.06,
P ¼ 0.02), (D) Albumin (r ¼ 0.75, P ¼ 0.2), and (E) nPCR (r ¼ 0.26, P ¼ 0.02).
cfDNA, cell-free DNA; Cr, creatinine; nPCR, normalized protein catabolic rate; SBP, systolic blood pressure; WBC, white blood cell.
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signiﬁcantly correlated.Multivariate analysis for the determinants of cfDNA in HD
patients
Table 2 presents multivariable regression analysis in total
HD patients, for the associations between log cfDNA levels and
the selected parameters that were associated with log cfDNA in
univariable analysis. Three-month mean SBP was the only in-
dependent determinant for the plasma level of cfDNA .We also
evaluated the independent parameters, which affect cfDNA in
diabetic patients using multivariable regression analysis.
Table 3 shows 3-month mean SBP and HbA1c were indepen-
dently associated with the plasma level of cfDNA in diabetic
patients.Table 2. Multivariate regression analysis of factors associated with
cfDNA level in hemodialysis patients
Parameters Beta coefﬁcient P
Sex 0.179 0.20
Age (y) 0.039 0.80
WBC (103/mL) 0.056 0.69
SBP (mmHg) 0.523 0.001
Total CV complication 0.169 0.24
Albumin (g/dL) 0.058 0.67
hsCRP (mg/L) 0.179 0.26
Cr (mg/dL) 0.149 0.34
nPCR (g/kg/d) e0.175 0.22
cfDNA, cell-free DNA; Cr, creatinine; CV, cardiovascular; hsCRP, high-
sensitivity C-reactive protein; nPCR, normalized protein catabolic rate;
SBP, systolic blood pressure; WBC, white blood cell.Discussion
In this study, the mean plasma cfDNA level in the HD pa-
tients was higher than that of the control group. Diabetic pa-
tients showed higher plasma cfDNA levels as compared to
nondiabetic HD patients. In addition, the cfDNA level was
signiﬁcantly correlated with current HbA1c levels in the dia-
betic HD patients. Patients with CV complications also showed
higher plasma cfDNA levels compared with those without CV
complication. A previous study suggested that the state of
uremia is associated with accelerated apoptosis of lympho-
cytes, monocytes, and neutrophils [15]. In dialysis patients,
chronic sterile inﬂammation is related to innate and adaptive
immune system activations, which result in an increased level
of inﬂammatory cytokines. In previous studies, increased
cfDNA levels were reported in HD patients, and cfDNA is able to
selectively induce the production of IL-6 in human monocytes
[14]. ESRD patients undergoing HD are characterized by
proinﬂammatory conditions. Various pathologic processes
occur in HD patients leading to their impaired function andTable 3. Multivariate regression analysis of factors associated with
cfDNA level in diabetic HD patients
Parameters Beta coefﬁcient P
Age (y) e0.019 0.93
Sex 0.270 0.22
SBP (mmHg) 0.525 0.02
WBC (103/mL) 0.265 0.19
HbA1c (%) 0.597 0.01
nPCR (g/kg/d) e0.013 0.59
hsCRP (mg/L) e0.144 0.57
Albumin (g/dL) 0.013 0.95
cfDNA, cell-free DNA; HbA1c, hemoglobin A1c; HD, hemodialysis; hsCRP,
high-sensitivity C-reactive protein; nPCR, normalized protein catabolic
rate; SBP, systolic blood pressure; WBC, white blood cell.
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deteriorating clinical conditions and with diabetes, CV disease,
infection, and malnutrition.
El Tarhouny et al [16] have reported that high levels of cfDNA
were present not only in the complicated group but also in the
diabetic patients without complications, although to a lesser
extent. Tovbin et al [13] have found that cfDNA levels correlate
with IL-6 and are particularly elevated in patients with proin-
ﬂammatory conditions, such as DM. The association among
cfDNA, IL-6, and diabetes is not surprising because both
inﬂammation and diabetes are destructive conditions that in-
crease cell death. Previous studies have reported that increased
cfDNA levels after acute ischemic stroke reﬂected the clinical
severity of ischemic stroke (in the acute stage) in patients, and a
study measuring cfDNA in rat models of focal brain ischemia
found correlations with the extent of ischemic injury, brain
edema, and neurologic outcomes in rats 24 hours after middle
cerebral artery occlusion. cfDNA levels have also been the focus
of extensive research diagnosing and monitoring malignancy,
acute myocardial infarct, and infection.
Among the clinical parameters, 3-month mean SBP was
independently correlated with the cfDNA level in HD patients
and diabetic HD patients. But there were few studies about
elevation of cfDNA and hypertension directly even if Levine
et al [17] have found elevation in cell-free fetal DNA inmaternal
plasma by pre-eclampsia, which is a hypertensive syndrome
that occurs only during pregnancy. Jylhava et al [18] demon-
strated that high levels of plasma cfDNA are closely linked with
the presence of cardiometabolic risks, including impaired
glucose tolerance (higher homeostasis assessment of insulin
resistance and insulin levels) and elevated blood pressure and
inﬂammatory cytokines [CRP, IL-6 and tumor necrosis factor
(TNF) a] in clinically healthy subjects. Therefore, this result that
cfDNAs are related with SBP in HD patients and diabetic HD
patients suggested that cfDNA elevation can be inﬂuenced by
hypertension like other diseases mentioned before. Recently,
the presence of free nucleic acids in the peripheral circulation,
referred to as cfDNA, has been proposed as a novel biomarker of
CV risk [19]. Amanda et al [20] demonstrated that cfDNA levels
are not inﬂuenced by renal impairment but do reﬂect endo-
thelial dysfunction in patients with chronic kidney disease
(CKD). Our data suggest that cfDNA could be an indicator of
vascular injury rather than proinﬂammatory marker. Our data
could not show the enough evidence of cfDNA enough as
proinﬂammatory marker (such as hsCRP) in HD patients. Tov-
bin et al [13] showed that the postdialysis cfDNA level was an
independent predictor of all-cause mortality in patients un-
dergoing HD.
There were limitations in this study. We did not show the
correlation with cfDNA in various inﬂammatory markers
because of the limitation of the study design and the small
number of patients. There is a need for large prospective studies
in different types of other inﬂammatory markers such as IL-6,
erythrocyte sedimentation rate, TNF a, and biomarker of
endothelial marker such as vonWillebrand factor. In this study,
age between HD patients and the control group shows a
considerable gap, and there was a concern that the gap might
affect the distinction of cfDNA level. In order to solve this
dispute,wecompared17patientswithHD (age, 34.9±2.7 years)
with 15 controls (age, 32.8 ± 1.2 years). And mean of cfDNA
levels of 17 patients with HD was still higher than 15 controls
(3,558.7 ± 45.7 GE/mL vs 1,420.0 ± 121.0 GE/mL, P < 0.05).In both univariable regression analysis and multivariable
regression analysis, age was not closely linked with plasma
cfDNA levels. Several other important clinical issues need
to consider whether physical activity, common vascular disease
risk factors (age, gender, smoking, and so forth), other con-
founding factors, and pharmacologic treatments affect the
quantity and quality of circulating cfDNA levels or not.
In conclusion, cfDNA was associated with the presence of
DM, comorbid condition of CV diseases, and SBP in HD patients.
It is the ﬁrst report that showed that uncontrolled hypertension
and poor glycemic control are independent determinants for
the elevated cfDNA in dialysis patients. Our data suggest that
cfDNA could be an indicator of vascular injury, especially in
diabetic HD patients.Conﬂicts of interest
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